Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2404213 | 0.80 | SIGMAR1 (0.42) | SIGMAR1CYP1A2CYP2D6ALDH1A1KDM4E | |
| SCHEMBL16667281 | 0.72 | HPGD (0.40) | SIGMAR1CYP1A2ALDH1A1 | |
| SCHEMBL18754041 | 0.71 | CXCR4 (0.56) | SIGMAR1LMNACXCR4 | |
| SCHEMBL1555898 | 0.69 | NPC1 (0.41) | SIGMAR1ALDH1A1KDM4E | |
| SCHEMBL1554923 | 0.69 | CYP3A4 (0.37) | SIGMAR1CYP1A2ALDH1A1KDM4E | |
| SCHEMBL2408399 | 0.68 | NPC1 (0.41) | SIGMAR1CYP1A2CYP2D6LMNAALDH1A1 | |
| SCHEMBL2406443 | 0.67 | KDM4E (0.40) | ALDH1A1KDM4E | |
| SCHEMBL171148 | 0.66 | SMN1; SMN2 (0.46) | SIGMAR1CYP1A2CYP2D6ALDH1A1KDM4E | |
| SCHEMBL2984679 | 0.65 | ADRB1 (0.73) | SIGMAR1CYP1A2CYP2D6LMNAADRB1 | |
| SCHEMBL2406071 | 0.65 | SMN1; SMN2 (0.45) | SIGMAR1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040259842-A1 | Intracellular calcuim concentration increase inhibitors | MIKOSHIBA, KATSUHIKO (JP) | 2004-12-23 | — | — | US | claimed |
| EP-1444981-A1 | INTRACELLULAR CALCIUM CONCENTRATION INCREASE INHIBITORS | Mikoshiba, Katsuhiko (JP) | 2004-08-11 | — | — | EP | claimed |
| US-20120316247-A1 | PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) | THE GENERAL HOSPITAL CORPORATION (US) | 2012-12-13 | — | — | US | disclosed |
| US-7217701-B2 | Intracellular calcium concentration increase inhibitors | KATSUHIKO MIKOSHIBA (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20040259842-A1 | Intracellular calcuim concentration increase inhibitors | MIKOSHIBA, KATSUHIKO (JP) | 2004-12-23 | — | — | US | disclosed |
| EP-1444981-A1 | INTRACELLULAR CALCIUM CONCENTRATION INCREASE INHIBITORS | Mikoshiba, Katsuhiko (JP) | 2004-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316247-A1 | PREVENTION AND TREATMENT OF POST-OPERATIVE COGNITIVE DYSFUNCTION (POCD) | CHAT, ACHE, BCHE | SIGMAR1 1205/4885CYP1A2 203/4885CYP2D6 164/4885 |
| US-20040259842-A1 | Intracellular calcuim concentration increase inhibitors | CAB39, BPGM, ORAI1 | SIGMAR1 2952/4885CYP1A2 4066/4885CYP2D6 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.